Dupilumab Treatment Beneficial for Sleep in Atopic Dermatitis
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 22, 2023 -- For adults with moderate-to-severe atopic dermatitis (AD), dupilumab treatment yields significant improvement in sleep quality and other AD-related signs and symptoms, according to a study published online Aug. 10 in the British Journal of Dermatology.
Joseph F. Merola, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a phase 4 randomized, double-blind study to examine the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes. Adults with moderate-to-severe AD were randomly assigned to dupilumab 300 mg once every two weeks (q2w; 127 participants) or placebo (61 participants) for 12 weeks. Subsequently, patients entered an open-label phase and received dupilumab 300 mg q2w for 12 weeks. Using a novel numeric rating scale (NRS), the primary end point was the percentage change from baseline to week 12 in sleep quality.
The researchers found a significant improvement in the sleep quality NRS in dupilumab-treated patients versus those receiving placebo by week 12 (least-squares mean difference, −15.5 percent). With dupilumab versus placebo, there were also significant differences in the peak pruritus NRS, SCORing Atopic Dermatitis (SCORAD), SCORAD sleep visual analog scale, and Patient Reported Outcomes Measurement Information System sleep-related impairment T-score. Compared with the placebo group, the dupilumab group had a lower overall percentage of patients reporting treatment-emergent adverse events.
"Future analyses will assess the persistence of dupilumab's effect on sleep disturbance through 24 weeks," the authors write.
Several authors disclosed ties to the pharmaceutical industry, including Sanofi and Regeneron Pharmaceuticals Inc., which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
RA Patients With Mono-, Oligo-Arthritis, High PGA Remain Most Fatigued
FRIDAY, June 28, 2024 -- Rheumatoid arthritis (RA) patients with mono- or oligo-arthritis and high Patient Global Assessment (PGA) at diagnosis remain the most fatigued, according...
Fatigue With Rheumatoid Arthritis Tied to Disease Activity, Education Level
WEDNESDAY, June 26, 2024 -- The Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ) and Brief Fatigue Inventory (BFI-C) scores show consistency in...
Longer Sleep Duration, Earlier Sleep Onset Linked to Lower BP in Children
TUESDAY, June 18, 2024 -- For children, longer sleep duration and earlier sleep onset are associated with lower blood pressure, according to a study published online June 18 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.